DUPIXENT Drug Insight and Market Forecast − 2032
“DUPIXENT Drug Insight and Market Forecast – 2032” report provides comprehensive insights about DUPIXENT for Eosinophilic esophagitis (EoE) in the seven major markets. A detailed picture of the DUPIXENT for EoE in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 –2032 is provided in this report along with a detailed description of the DUPIXENT for EoE. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the DUPIXENT market forecast analysis for EoE in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in EoE.
Dupilumab is a human monoclonal IgG4 antibody that inhibits IL-4 and IL-13 signaling by specifically binding to the IL-4Rα subunit shared by the IL-4 and IL-13 receptor complexes. It inhibits IL-4 signaling via the type I receptor and IL-4 and IL-13 signaling through the type II receptor. Data from DUPIXENT clinical trials have shown that IL-4 and IL-13 are key drivers of the type 2 inflammation that plays a major role in atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyposis (CRSwNP), and EoE. Blocking IL-4Rα with dupilumab inhibits IL-4 and IL-13 cytokine-induced inflammatory responses, including the release of pro-inflammatory cytokines, chemokines, nitric oxide, and IgE. Dupilumab was invented using Regeneron’s proprietary VelocImmune technology. VelocImmune is a unique technology for producing fully human monoclonal antibodies.
According to the company, DUPIXENT is the first and only biologic to show positive and clinically-meaningful Phase III results in patients 12 years and older with EoE. The company is also evaluating dupilumab in Phase III (EoE KIDS) study in pediatric patients with active EoE. Additionally, FDA has granted BTD, ODD, and PR.
Scope of the Report
The report provides insights into:
A comprehensive product overview including the DUPIXENT description, mechanism of action, dosage and administration, research and development activities in eosinophilic esophagitis (EoE).
Elaborated details on DUPIXENT regulatory milestones and other development activities have been provided in this report.
The report also highlights the DUPIXENT research and development activities in EoE across the United States, Europe and Japan.
The report also covers the patents information with expiry timeline around DUPIXENT.
The report contains forecasted sales of DUPIXENT for EoE till 2032.
Comprehensive coverage of the late-stage emerging therapies for EoE.
The report also features the SWOT analysis with analyst views for DUPIXENT in EoE.
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
DUPIXENT Analytical Perspective by DelveInsight
In-depth DUPIXENT Market Assessment
This report provides a detailed market assessment of DUPIXENT for eosinophilic esophagitis (EoE) in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2023 to 2032.
DUPIXENT Clinical Assessment
The report provides the clinical trials information of DUPIXENT for EoE covering trial interventions, trial conditions, trial status, start and completion dates.
In the coming years, the market scenario for eosinophilic esophagitis (EoE) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence DUPIXENT dominance.
Other emerging products for EoE are expected to give tough market competition to DUPIXENT and launch of late-stage emerging therapies in the near future will significantly impact the market.
A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of DUPIXENT in EoE.
Our in-depth analysis of the forecasted sales data of DUPIXENT from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the DUPIXENT in EoE.
What is the product type, route of administration and mechanism of action of DUPIXENT?
What is the clinical trial status of the study related to DUPIXENT in eosinophilic esophagitis (EoE) and study completion date?
What are the key collaborations, mergers and acquisitions, licensing and other activities related to the DUPIXENT development?
What are the key designations that have been granted to DUPIXENT for EoE?
What is the forecasted market scenario of DUPIXENT for EoE?
What are the forecasted sales of DUPIXENT in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
What are the other emerging products available and how are these giving competition to DUPIXENT for EoE?
Which are the late-stage emerging therapies under development for the treatment of EoE?